{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:06:57Z","timestamp":1784779617841,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012775","name":"Royal Melbourne Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Allogeneic stem cell transplantation (alloSCT) is utilised to cure haematological malignancies through a combination of conditioning regimen intensity and immunological disease control<jats:italic>via<\/jats:italic>the graft versus tumour (GVT) effect. Currently, conventional myeloablative chemotherapeutic or chemoradiation conditioning regimens are associated with significant side effects including graft versus host disease (GVHD), infection, and organ toxicity. Conversely, more tolerable reduced intensity conditioning (RIC) regimens are associated with unacceptably higher rates of disease relapse, partly through an excess incidence of mixed chimerism. Improvement in post-alloSCT outcomes therefore depends on promotion of the GVT effect whilst simultaneously reducing conditioning-related toxicity. We have previously shown that this could be achieved through BCL-2 inhibition, and in this study, we explored the modulation of JAK1\/2 as a strategy to lower the barrier to donor engraftment in the setting of RIC. We investigated the impact of short-term treatment of BCL2 (venetoclax) or JAK1\/2 (ruxolitinib) inhibition on recipient natural killer and T cell immunity and the subsequent effect on donor engraftment. We identified striking differences in mechanism of action of these two drugs on immune cell subsets in the bone marrow of recipients, and in the regulation of MHC class-II and interferon-inducible gene expression, leading to different rates of GVHD. This study demonstrates that the repurposed use of ruxolitinib or venetoclax can be utilised as pre-transplant immune-modulators to promote the efficacy of alloSCT, whilst reducing its toxicity.<\/jats:p>","DOI":"10.3389\/fimmu.2021.749094","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:32:00Z","timestamp":1632529920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients"],"prefix":"10.3389","volume":"12","author":[{"given":"Joanne E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy J.","family":"Ludford-Menting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvind","family":"Prabahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Koldej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/s2352-3026(15)00028-9","article-title":"One Million Haemopoietic Stem-Cell Transplants: A Retrospective Observational Study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current Use of and Trends in Hematopoietic Cell Transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","volume-title":"Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR US Summary Slide","author":"Phelan","year":"2020"},{"key":"B4","volume-title":"Australasian Bone Marrow Transplant Recipient Registry: Annual Data Summary","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.01.086","article-title":"Prognostic Limitations of Donor T Cell Chimerism After Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"23","author":"Wong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2021.1910688","article-title":"Inferior Outcomes With Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Fit Individuals With Acute Lymphoblastic Leukemia: A Canadian Single-Center Study and a Comparison to Registry Data","volume":"62","author":"Pasic","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0228-y","article-title":"Recipient BCL2 Inhibition and NK Cell Ablation Form Part of a Reduced Intensity Conditioning Regime That Improves Allo-Bone Marrow Transplantation Outcomes","volume":"26","author":"Jiao","year":"2019","journal-title":"Cell Death Differ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.003","article-title":"A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-Versus-Host Disease in Mice","volume":"21","author":"Davis","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in Corticosteroid-Refractory Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation: A Multicenter Survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The Development of Ruxolitinib for Glucocorticoid-Refractory Acute Graft-Versus-Host Disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the Treatment of Steroid-Refractory Acute GVHD (REACH1): A Multicenter, Open-Label Phase 2 Trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-Versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible Defects in Natural Killer and Memory CD8 T Cell Lineages in Interleukin 15-Deficient Mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J Exp Med"},{"key":"B17","article-title":"Predictive Observation-Based Endpoint Criteria for Mice Receiving Total Body Irradiation","volume":"63","author":"Nunamaker","year":"2013","journal-title":"Comp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ni1487","article-title":"Interleukin 15-Mediated Survival of Natural Killer Cells Is Determined by Interactions Among Bim, Noxa and Mcl-1","volume":"8","author":"Huntington","year":"2007","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3470","article-title":"CIS Is a Potent Checkpoint in NK Cell-Mediated Tumor Immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-171942","article-title":"Viperin Is Required for Optimal Th2 Responses and T-Cell Receptor-Mediated Activation of NF-KappaB and AP-1","volume":"113","author":"Qiu","year":"2009","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.10.5917","article-title":"Mouse NKR-P1B, a Novel NK1.1 Antigen With Inhibitory Function","volume":"162","author":"Carlyle","year":"1999","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.immuni.2019.08.011","article-title":"MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-Versus-Host Disease and Is Influenced by the Microbiota","volume":"51","author":"Koyama","year":"2019","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02308","article-title":"Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.Ccr-10-1198","article-title":"Interleukin-6 Modulates Graft-Versus-Host Responses After Experimental Allogeneic Bone Marrow Transplantation","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009050","article-title":"A Phase 3 Double-Blind Study of the Addition of Tocilizumab vs Placebo to Cyclosporin\/Methotrexate GVHD Prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-Inhibitor Ruxolitinib Impairs Dendritic Cell Function In Vitro and In Vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.01.012","article-title":"Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Patients After Allogeneic Stem Cell Transplantation","volume":"26","author":"Zhao","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation Ruxolitinib Prevents Acute Graft-Versus-Host Disease in Patients With Myelofibrosis Undergoing Allogenic Stem Cell Transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.749094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T03:38:59Z","timestamp":1673321939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.749094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2021.749094"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.749094","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"article-number":"749094"}}